Your browser doesn't support javascript.
loading
Peripheral venous congestion causes time- and dose-dependent release of endothelin-1 in humans.
Lin, Jeffrey; Chudasama, Neelesh; Hayashi, Yacki; Hawk, Christopher; Ramnauth, Sahadeo D; Wong, Ka Yuk; Harxhi, Ante; Onat, Duygu; Wakabayashi, Michiyori; Uriel, Nir; Jorde, Ulrich P; LeJemtel, Thierry H; Sabbah, Hani N; Demmer, Ryan T; Colombo, Paolo C.
Afiliación
  • Lin J; Columbia University Medical Center, New York, New York.
  • Chudasama N; Columbia University Medical Center, New York, New York.
  • Hayashi Y; Columbia University Medical Center, New York, New York.
  • Hawk C; Columbia University Medical Center, New York, New York.
  • Ramnauth SD; Columbia University Medical Center, New York, New York.
  • Wong KY; Columbia University Medical Center, New York, New York.
  • Harxhi A; Columbia University Medical Center, New York, New York.
  • Onat D; Columbia University Medical Center, New York, New York.
  • Wakabayashi M; Columbia University Medical Center, New York, New York.
  • Uriel N; Columbia University Medical Center, New York, New York.
  • Jorde UP; Columbia University Medical Center, New York, New York.
  • LeJemtel TH; Tulane University School of Medicine, New Orleans, Louisiana.
  • Sabbah HN; Medicine, Henry Ford Hospital, Detroit, Michigan.
  • Demmer RT; Columbia University Medical Center, New York, New York.
  • Colombo PC; Columbia University Medical Center, New York, New York pcc2001@columbia.edu.
Physiol Rep ; 5(6)2017 Mar.
Article en En | MEDLINE | ID: mdl-28320895
ABSTRACT
Endothelin-1 (ET-1) is a pivotal mediator of vasoconstriction and inflammation in congestive states such as heart failure (HF) and chronic kidney disease (CKD). Whether peripheral venous congestion (VC) increases plasma ET-1 at pressures commonly seen in HF and CKD patients is unknown. We seek to characterize whether peripheral VC promotes time- and dose-dependent increases in plasma ET-1 and whether these changes are sustained after decongestion. We used a randomized, cross-over design in 20 healthy subjects (age 30 ± 7 years). To experimentally model VC, venous pressure was increased to either 15 or 30 mmHg (randomized at first visit) above baseline by inflating a cuff around the subject's dominant arm; the nondominant arm served as a noncongested control. We measured plasma ET-1 at baseline, after 20, 60 and 120 min of VC, and finally at 180 min (60 min after cuff release and decongestion). Plasma ET-1 progressively and significantly increased over 120 min in the congested arm relative to the control arm and to baseline values. This effect was dose-dependent ET-1 increased by 45% and 100% at VC doses of 15 and 30 mmHg, respectively (P < 0.05), and declined after 60 min of decongestion though remaining significantly elevated compared to baseline. In summary, peripheral VC causes time- and dose-dependent increases in plasma ET-1. Of note, the lower dose of 15 mmHg (more clinically relevant to HF and CKD patients) was sufficient to raise ET-1. These findings support the potentially contributory, not merely consequential, role of VC in the pathophysiology of HF and CKD.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vasoconstricción / Presión Venosa / Endotelina-1 Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Physiol Rep Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vasoconstricción / Presión Venosa / Endotelina-1 Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Physiol Rep Año: 2017 Tipo del documento: Article